ACE2 and COVID-19: Improved insulin resistance tracks with reductions in angiotensin-converting enzyme 2 (ACE2), and this may have a direct effect on COVID-19 risk, given the role of ACE2 in binding the severe acute respiratory syndrome coronavirus 2 pathogen [35,36].